REDWOOD CITY, Calif. - Codexis , Inc. (NASDAQ: NASDAQ:CDXS), a key player in the enzymatic solutions sector, has fortified its financial position by raising $31 million through its at-the-market (ATM) offering in the quarter ending September 30, 2024. This capital boost supplements the company's previously reported $73.2 million in cash and investments as of June 30, 2024, and is projected to extend its cash runway into 2027.
The company has also announced significant leadership appointments, with Alison Moore, PhD, stepping into the role of Chief Technology Officer, and Georgia Erbez as Chief Financial Officer. John Schiffhauer joins as Senior Vice President of Intellectual Property. These strategic hires are part of Codexis' preparation for its next growth phase, particularly in the manufacturing of siRNA therapeutics.
Chairman and CEO Stephen Dilly expressed confidence that the new leadership additions, with their extensive experience, will be instrumental in executing the company's strategic objectives. Dr. Moore, recognized for her expertise in biomanufacturing, has been associated with Codexis' board for four years. Erbez brings a wealth of financial acumen from her previous roles in various biotechnology firms.
Codexis is on the verge of launching an innovative platform for the efficient production of siRNA therapeutics, known as the ECO Synthesis™ Manufacturing Platform. The company has presented promising data that suggests this platform could overcome the scalability and cost limitations of traditional phosphoramidite chemistry used in oligonucleotide synthesis.
The company continues to expand its senior leadership with individuals who possess critical skills to support its evolution as an siRNA manufacturer. This includes the recent appointment of Britton Jimenez as Senior Vice President, Commercial Operations, and Schiffhauer, who brings over two decades of legal and intellectual property experience to the company.
Codexis' growth strategy and operational enhancements are based on leveraging its proprietary CodeEvolver® technology platform to develop high-performance enzymes for pharmaceutical manufacturing and nucleic acid synthesis. The company's efforts aim to improve yields, reduce waste, and enhance manufacturing efficiency across various applications.
This announcement is based on a press release statement from Codexis, Inc.
In other recent news, Codexis, Inc. has reported Q2 2024 revenues of $8 million, with projections of double-digit product revenue growth for 2024. This growth is expected to be driven by its pharmaceutical manufacturing business and the development of its ECO Synthesis platform for siRNA therapeutics. Piper Sandler, maintaining its Overweight rating for Codexis, has kept a steady price target of $10.00 based on these recent developments.
The company's strategic focus on the production of RNAi therapeutics through its proprietary ECO Synthesis platform has been acknowledged by Piper Sandler as beneficial. Codexis' recent success in commercializing its dsRNA ligase program has also contributed to its strong performance. The company aims to achieve positive cash flow by the end of 2026, leveraging its pharmaceutical manufacturing pipeline and ligase orders.
In further developments, Codexis plans to become a Contract Development and Manufacturing Organization (CDMO) and aims to produce GLP-grade siRNA in 2025. These recent developments underscore the company's commitment to growth and innovation. As per Piper Sandler, Codexis' operational strategy and its execution reflect potential for future growth.
InvestingPro Insights
Codexis Inc.'s recent capital raise of $31 million through its ATM offering aligns with the company's financial strategy, as reflected in the InvestingPro data. The company's market cap stands at $219.17 million, indicating its current valuation in the market.
An InvestingPro Tip highlights that Codexis holds more cash than debt on its balance sheet, which is consistent with the company's efforts to strengthen its financial position. This cash-rich status, combined with the recent capital raise, supports the company's projection of extending its cash runway into 2027.
However, another InvestingPro Tip points out that Codexis is quickly burning through cash. This information provides context to the company's decision to raise additional capital and underscores the importance of the new leadership appointments in steering the company towards profitability.
The company's revenue for the last twelve months as of Q2 2024 was $60.89 million, with a concerning revenue growth of -38.59% over the same period. This decline in revenue growth emphasizes the need for Codexis to successfully launch and commercialize its ECO Synthesis™ Manufacturing Platform for siRNA therapeutics.
It's worth noting that InvestingPro offers 7 additional tips for Codexis, providing a more comprehensive analysis for investors interested in delving deeper into the company's financial health and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.